Amendment 001 Revised Att H Subsistence IPP 10.20.21.pdf

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

1 1

2. AMENDMENT/MODIFICATION NO.

A00001

3. EFFECTIVE DATE

See Block 16C

4. REQUISITION / PURCHASE REQ. NO.

PROJECT NO. (If Applicable)

6. ISSUED BY

Federal Bureau of Prisons Residential Reentry Contracting Office 320 First Street NW, Room 901-5 Washington, D.C. 20534

CODE 7. ADMINISTERED BY (If other than Item 6)

CODE

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

(√) 9A. AMENDMENT OF SOLICITATION NO

RFP 15BRRC21R00000357

9B. DATED (See Item 11)

10/15/2021

10A. MODIFICATION OF CONTRACT/ORDER NO.

CODE FACILITY CODE 10B. DATED (See Item 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

[X ] The above number solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers [ ] is extended, [ x ] is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods.

(a) By completing Items 8 and 15, and returning 1 copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OR CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

x A. THE CHANGE ORDER IS ISSUED PURSUANT TO: (Specify Authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

52.243-1 Alternate I – Changes Fixed Price

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor [ ] is not [ x ] is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible).

RFP 15BRRC21R00000357, for Residential Reentry Center (RRC) services located within the city limits of Bridgeton, New Jersey, and Home Confinement services within 100 radius miles of the RRC facility, is hereby amended as follows:

1. In Section J, Statement of Work (SOW)

Drug Testing Replace Attachment H (see attached). This corrects the language and cut-off levels for urinalysis testing currently used by the Bureau of Prisons. Also, replace the sentence of the SOW which states “Upon approval of the RRM, the contractor may exercise the option of employing alternative methods of testing (e.g., test cup, or strip test)” with “The contractor may exercise the option of employing alternative methods of testing (e.g. test cup, or strip test).”

Subsistence Any reference to subsistence collection shall be removed from all RRC Statement of Work and will no longer be required. Subsistence will not be collected from any resident.

Individualized Program Plan (IPP) Add the following sentence in Chapter 10 – Programs under Individualized Program Plan (IPP): The IPP must be loaded into R3M after every bi-weekly plan update in .pdf format.

//All other terms and conditions remain the same.//

Except as provided herein, all items and conditions of the document referenced in item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Tana Jankowiak

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED 16B. UNITED STATES OF AMERICA

BY //s//

(Signature of Contracting Officer)

16C. DATE SIGNED

10/20/2021

STANDARD FORM 30 (REV. 11/2016)

PREVIOUS EDITION UNUSABLE Prescribed by GSA FAR (48 CFR) 53.243

ATTACHMENT H

Contractor shall conduct specimen validity testing and use an Immunoassay test methodology to screen specimens for the presence of the following drugs at the listed cutoffs:

DRUG SCREEN

Amphetamines(Amphetamine, Methamphetamine) 500 ng/mL MDMA, MDA, MDEA (Ecstasy, Adam, Eve) 500 ng/mL Benzoylecgonine 150 ng/mL Cannabinoids 50 ng/mL Opiates (Morphine, Codeine, Hydromorphone [Dilaudid], Hydrocodone)

300 ng/mL

Oxycodone, Oxymorphone 100 ng/mL

Specimen Validity Testing As part of the screening test panel, individual special tests, and GC/MS confirmation only testing, the contractor shall perform a specimen validity panel to assess the integrity of the specimen provided. This panel shall include tests for specific gravity, pH, and Creatinine. If the specimen shows signs of adulteration by an in-vitro substance other than water, an attempt must be made to identify the adulterant and, if identified, the adulterant shall be reported. When requested, the contractor shall also provide interpretation of the values reported as part of the adulteration panel utilizing PC 1100. The contractor shall report results of the specimen validity panel utilizing the following criteria:

Dilute:

Creatinine equal to or greater than 2 mg/dL and less than or equal to 20 mg/dL (quantitation to one decimal place)

AND/OR

Specific gravity lower than 1.0030 (quantitation to four decimal places) Report as: “Specimen dilute” Substituted:

Creatinine less than 2 mg/dL (quantitation to one decimal place) Report as: “Specimen not consistent with normal human urine.”

Invalid:

Specific gravity equal to or less than 1.0010, or equal to or greater than 1.0450 (quantitation to four decimal places) Report as: “Specimen invalid, not consistent with normal human urine.”

NOTE: The vendor shall only report negative specimens as invalid. Positive specimens that meet the criteria for invalid shall be reported as positive only.

Adulterated:

pH less than 4 or equal to or greater than 10 Report as: “Specimen adulterated, pH is too low (or too high)” Other Adulterants A foreign substance not known to occur in human urine or at a concentration that exceeds normal levels in human urine is identified (e.g., greater than 500 micrograms/mL of nitrites) Report as: “Specimen adulterated, presence of ________ (list the name of substance(s) and/or adulterant(s) detected)”

If a resident receives a positive test then the contractor shall screen and conduct specimen validity testing for any or all of the following drugs (each shall be requested as an individual drug screen) using the methods and sensitivity listed below:

DRUG SCREEN CUTOFF CONFIRMATION

METHODOLOGY

CUTOFF

d-Lysergic Acid Diethylamide (LSD)

IA < or = 0.5 ng/mL

LC/MS/MS or

GC/MS

< or = 0.5 ng/mL

Anabolic Steroids GC/MS Pos/Neg LC/MS/MS or

GC/MS

Pos/Neg

Ethanol Colormetric 0.2 g/dl GC 0.02% g/dl Barbiturates IA 200 LC/MS/MS or

GC/MS

200 ng/mL

Benzodiazepines IA 200 LC/MS/MS or

GC/MS

200 ng/mL

Methadone IA 200 LC/MS/MS or

GC/MS

300 ng/mL

6-Acetylmorphine

(6-AM)

IA 10 ng/mL LC/MS/MS or

GC/MS

10 ng/mL

Phencyclidine (PCP) IA 25ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Buprenorphine IA 10 LS/MS/MS or

GC/MS

5 ng/mL

Gammahydroxybutyric GC 10 GC 10 ng/mL Ketamine GC/MS 300 LC/MS/MS or

GC/MS

300 ng/mL

Fentanyl IA 2 LC/MS/MS or

GC/MS

0.5 ng/mL

Propoxyphene IA 300 LC/MS/MS or

GC/MS

300 ng/mL

Gabapentin IA 100 ng/mL LC/MS/MS or

GC/MS

100 ng/mL

Tramadol IA 100 ng/mL LC/MS/MS or

GC/MS

100 ng/mL

Mitragynine (Kratom)

IA 25 ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Synthetic Stimulants

IA 25 ng/mL LC/MS/MS or

GC/MS

25 ng/mL

Synthetic Cannanbinoids

IA 25 ng/mL LC/MS/MS or

GC/MS

1 ng/mL